Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for EBV infection and post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation
ChiCTR1800014960Phase 4Recruiting
- Sponsor
- Shanghai Children's Medical Center
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in Epstein-Barr virus infection and Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by Shanghai Children's Medical Center. Primary endpoints: response, partial response and 1 more. Started Mar 2018; status: recruiting.
02
Drugs
rituximab
03
Conditions
Epstein-Barr virus infectionPost-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on ChiCTR1800014960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014960.